Low-dose gemcitabine plus nab-paclitaxel
chemotherapy
elderly
gemcitabine
nab‐paclitaxel
pancreatic cancer
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
01
03
2023
accepted:
27
08
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
A multicenter, open-label randomized Phase II trial was conducted to determine whether low-dose gemcitabine plus nab-paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard-dose GnP for elderly patients with metastatic pancreatic cancer. Consecutive patients aged ≥65 years with metastatic pancreatic cancer who presented at one of four Japanese referral centers between November 2016 and January 2021 were enrolled. The 60 patients were randomly assigned to low- or standard-dose groups with a 1:1 ratio. Patients in the low-dose GnP group received gemcitabine at a dose of 250 mg/m Low-dose GnP significantly decreased the rate of cases requiring dose reduction (16.7% Low-dose GnP had an equivalent efficacy to conventional therapy; however, it did not reduce adverse events.
Sections du résumé
Background and Aim
UNASSIGNED
A multicenter, open-label randomized Phase II trial was conducted to determine whether low-dose gemcitabine plus nab-paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard-dose GnP for elderly patients with metastatic pancreatic cancer.
Methods
UNASSIGNED
Consecutive patients aged ≥65 years with metastatic pancreatic cancer who presented at one of four Japanese referral centers between November 2016 and January 2021 were enrolled. The 60 patients were randomly assigned to low- or standard-dose groups with a 1:1 ratio. Patients in the low-dose GnP group received gemcitabine at a dose of 250 mg/m
Results
UNASSIGNED
Low-dose GnP significantly decreased the rate of cases requiring dose reduction (16.7%
Conclusion
UNASSIGNED
Low-dose GnP had an equivalent efficacy to conventional therapy; however, it did not reduce adverse events.
Identifiants
pubmed: 37744711
doi: 10.1002/jgh3.12966
pii: JGH312966
pmc: PMC10517437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
659-666Informations de copyright
© 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Eur J Cancer. 2021 Jan;143:101-112
pubmed: 33296830
J Geriatr Oncol. 2022 Jan;13(1):82-87
pubmed: 34215525
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
Jpn J Clin Oncol. 2018 Nov 1;48(11):1028-1029
pubmed: 30304484
Int J Clin Oncol. 2011 Dec;16(6):637-45
pubmed: 21519814
Cancer Chemother Pharmacol. 2016 Mar;77(3):595-603
pubmed: 26842789
J Clin Oncol. 2011 Dec 1;29(34):4548-54
pubmed: 21969517
Therap Adv Gastroenterol. 2020 Nov 24;13:1756284820974912
pubmed: 33281939
J Clin Oncol. 1991 Mar;9(3):491-8
pubmed: 1999720
J Gastroenterol. 2006 Jan;41(1):70-6
pubmed: 16501860
Eur J Cancer. 2010 Jun;46(9):1502-13
pubmed: 20227872
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Cancer Chemother Pharmacol. 2017 Apr;79(4):813-823
pubmed: 28251282
Pancreatology. 2020 Jan;20(1):95-100
pubmed: 31786057
Pancreatology. 2021 May 24;:
pubmed: 34090806
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140